Document is current
Any future updates will be listed below
-
Authors
Wongtangman, Karuna
reddy Janga, Siddhartha
Azimaraghi, Omid
Khandaker, Rafi
Khera, Tanvi
Leff, Jonathan
Forest, Stephen J.
Suleiman, Aiman
Tam, Christopher
Spindel, Stephen
DeYoung, Pamela N.
Malhotra, Atul
Subramaniam, Balachundhar
Eikermann, Matthias https://orcid.org/0000-0002-7893-0596
-
Funding
Funding for this research was provided by:
Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Kenilworth, New Jersey, USA
- License Information
-
More Information
Article History
Received: 21 March 2026
Accepted: 18 June 2026
First Online: 23 June 2026
Declarations
:
: This study was approved by the Institutional review boards at both Albert Einstein College of Medicine/Montefiore Health System (2021–13369) and Beth Israel Deaconess Medical Center (2019-P0000759). Written informed consent was obtained from all subjects or their legally authorised representatives.
: Not applicable.
: Matthias Eikermann received compensation for serving on the advisory board for Suvorexant. He is funded by Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Kenilworth, New Jersey, USA for this study.
